COVID-19: Lagos To Use 600 Patients For Chloroquine Clinical Trial
The state’s Commissioner for Information, Gbenga Omotosho, who disclosed this stated that;
In summary, we will be looking at about 600 patients. The trial will go on till we recruit the required number.
There will be an independent Data and Safety Board. The board can advise that the study be discontinued if the statistical evidence of the usefulness of the drug is overwhelming and in which case it becomes unethical to withhold it from other groups.
Speaking as well, Governor Babajide Sanwo-Olu, said the state had learnt how to deal with infectious diseases, through its handling of the Ebola pandemic in 2014.
He stressed that;
The Ebola pandemic was also epic in Lagos and it gave Lagos some understanding about how serious infectious disease could be managed. We have an Infectious Disease Hospital in Yaba and even after the Ebola case, we had some international grants and over the last two to three years, we have built what we call a biosecurity lab level four, which can match any of its kind in the world.
The Lagos State Commissioner for Health, Akin Abayomi, had earlier in April said the state was going to hold clinical trials.
The adaptation of chloroquine for clinical trial as a potential drug in managing COVID-19 is based on data from other treatment centres across the world.
Last month, US Food and Drug Administration warned health professionals that the drug should not be used to treat COVID-19 outside of hospital or for research purposes, as it is likely to cause “serious heart rhythm problems in patients with COVID-19.”